Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Non-Current Assets (2018 - 2025)

BioNexus Gene Lab's Non-Current Assets history spans 8 years, with the latest figure at $2.0 million for Q3 2025.

  • For Q3 2025, Non-Current Assets fell 49.58% year-over-year to $2.0 million; the TTM value through Sep 2025 reached $2.0 million, down 49.58%, while the annual FY2024 figure was $3.0 million, 10.43% down from the prior year.
  • Non-Current Assets for Q3 2025 was $2.0 million at BioNexus Gene Lab, down from $3.0 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $4.0 million in Q3 2024 and bottomed at $2.0 million in Q3 2025.
  • The 5-year median for Non-Current Assets is $2.7 million (2022), against an average of $2.8 million.
  • The largest annual shift saw Non-Current Assets skyrocketed 706.39% in 2021 before it plummeted 49.58% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $2.4 million in 2021, then increased by 12.12% to $2.7 million in 2022, then rose by 23.35% to $3.4 million in 2023, then dropped by 10.43% to $3.0 million in 2024, then crashed by 33.59% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Non-Current Assets are $2.0 million (Q3 2025), $3.0 million (Q2 2025), and $2.9 million (Q1 2025).